The approval, granted recently by Health Canada, will give Nutrasource’s clients an accelerated path to cannabis human research authorizations. Historically, that process could be uncertain and prolong timelines when submitting individual projects on a stand-alone basis.
“This license is pivotal for our client base given that regulatory approval delays in this product category have been unpredictable, which adds substantially to the client’s project timelines and cost,” said William Rowe, President and CEO of Nutrasource.
This Institution-wide Cannabis Research License allows Nutrasource to:
- Expedite government approvals that will allow all human research to be conducted at the Nutrasource site without applying for multiple licenses each time a study is conducted;
- Run multiple research projects at the same site for various clients simultaneously; and
- Conduct studies (clinical and efficacy trials, sensory, pharmacokinetic, pharmacodynamic and palatability studies) that would include participants.
Joshua Baisley, VP of Clinical Trial Design & Delivery, added: “As leaders in providing clinical trial services to the global cannabis industry, this institution-wide license adds additional benefit to the favorable Canadian regulatory environment, including (CTA) Clinical Trial Applications for human studies in this expansive product category.”
